{"id":582735,"date":"2026-08-12T20:14:09","date_gmt":"2026-08-12T20:14:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/582735\/"},"modified":"2026-08-12T20:14:09","modified_gmt":"2026-08-12T20:14:09","slug":"seeking-mesothelioma-patients-for-new-cell-therapy-trial","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/582735\/","title":{"rendered":"Seeking Mesothelioma Patients for New Cell Therapy Trial"},"content":{"rendered":"<p>        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/scientists.jpg\" alt=\"Scientists\" class=\"o-image c-figure__image\" width=\"568\" height=\"319\"\/><\/p>\n<p>A clinical trial testing a new type of cell therapy for mesothelioma is actively recruiting patients at sites across the country, including Moffitt Cancer Center in Tampa, Florida. This is an early-stage trial.<\/p>\n<p>The therapy, called SynKIR-110, is a lab-engineered cell treatment designed to target mesothelin, a protein found on the surface of most mesothelioma tumor cells. The trial is open to patients with either <a href=\"https:\/\/www.asbestos.com\/mesothelioma\/pleural\/\" rel=\"nofollow noopener\" target=\"_blank\">pleural mesothelioma<\/a> or <a href=\"https:\/\/www.asbestos.com\/mesothelioma\/peritoneal\/\" rel=\"nofollow noopener\" target=\"_blank\">peritoneal mesothelioma<\/a>, as well as ovarian cancer and cholangiocarcinoma. Early results were presented this year at a major cancer research conference.<\/p>\n<p>Dr. Janos Tanyi, the trial\u2019s principal investigator and a professor at the University of Pennsylvania\u2019s Perelman School of Medicine, said the early data support continuing to study the approach. \u201cThese data are significant because patients with mesothelin-expressing solid tumors continue to face significant and urgent needs for better treatments,\u201d he told us.\u00a0<\/p>\n<p>Results So Far From STAR-101<\/p>\n<p>Researchers found tumor shrinkage for 1 of 3 patients at the highest dose level of SynKIR-110 tested so far, classified as a partial response. That response was still ongoing after 3 months. The trial, known as <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05568680\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">STAR-101<\/a>, is still working out the right dose, so enrollment and dose escalation are ongoing.<\/p>\n<p>Pointing to the trial\u2019s safety results specifically, Dr. Tanyi noted that only 3 out of 9 patients treated so far had mild cytokine release syndrome. This is a common and usually manageable side effect of cell therapies, and no patients had neurotoxicity. In the first nine patients treated, no dose-limiting side effects, no severe cytokine release syndrome and no neurotoxicity were reported.<\/p>\n<p>How the Therapy Works<\/p>\n<p>SynKIR-110 is built from a patient\u2019s own T cells, a type of immune cell, which are collected, modified in a lab, then infused back into the patient. The modification trains those T cells to recognize and attack tumor cells that carry high levels of mesothelin, a protein overexpressed in <a href=\"https:\/\/www.asbestos.com\/mesothelioma\/\" rel=\"nofollow noopener\" target=\"_blank\">mesothelioma<\/a> and a small number of other cancers.<\/p>\n<p>What sets this therapy apart from earlier <a href=\"https:\/\/www.asbestos.com\/treatment\/immunotherapy\/car-t-cell-therapy\/\" rel=\"nofollow noopener\" target=\"_blank\">CAR T-cell treatments<\/a> is its design. Traditional CAR T-cells often wear out over time, a problem called T-cell exhaustion This particularly happens when fighting solid tumors like mesothelioma rather than blood cancers. SynKIR-110 uses a different signaling structure, borrowed in part from natural killer cells, intended to keep the T cells active longer.<\/p>\n<p>How to Join the STAR-101 Clinical Trial<\/p>\n<p>People with advanced pleural or peritoneal mesothelioma whose tumors express mesothelin, are eligible to enroll. <a href=\"https:\/\/www.asbestos.com\/cancer-centers\/h-lee-moffitt-cancer-center\/\" rel=\"nofollow noopener\" target=\"_blank\">Moffitt Cancer Center<\/a> in Tampa, the <a href=\"https:\/\/www.asbestos.com\/cancer-centers\/abramson-cancer-center\/\" rel=\"nofollow noopener\" target=\"_blank\">University of Pennsylvania<\/a> and <a href=\"https:\/\/www.asbestos.com\/cancer-centers\/md-anderson-texas\/\" rel=\"nofollow noopener\" target=\"_blank\">MD Anderson Cancer Center<\/a> in Houston, where Dr. Mehmet Altan is a site investigator, are all enrolling patients.\u00a0<\/p>\n<p>Additional sites nationwide are as well. The trial\u2019s developer, Verismo Therapeutics, has continued to expand access to new locations as enrollment continues.<\/p>\n<p>If you\u2019re interested in more information or enrolling in the trial, a <a href=\"https:\/\/www.asbestos.com\/patient-resources\/patient-advocates\/\" rel=\"nofollow noopener\" target=\"_blank\">Patient Advocate<\/a> or your <a href=\"https:\/\/www.asbestos.com\/treatment\/doctors\/\" rel=\"nofollow noopener\" target=\"_blank\">mesothelioma doctor<\/a> can help you. SynKIR-110 remains investigational. It isn\u2019t an approved <a href=\"https:\/\/www.asbestos.com\/treatment\/\" rel=\"nofollow noopener\" target=\"_blank\">mesothelioma treatment<\/a> yet.<\/p>\n<p>Results of this <a href=\"https:\/\/www.asbestos.com\/treatment\/clinical-trials\/\" rel=\"nofollow noopener\" target=\"_blank\">clinical trial<\/a> so far come from a small group of patients across the first few dose levels tested. Researchers are still determining the right dose to carry into further study. But early safety data without serious side effects, paired with a tumor response in a heavily pretreated cancer, is the kind of early signal that keeps a solid-tumor cell therapy trial worth watching.<\/p>\n<p>        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.asbestos.com\/wp-content\/uploads\/free-medical-care-icon-icon.svg\" alt=\"blue medical health symbol\" class=\"o-image  c-cta__image\" width=\"64\" height=\"64\"\/><\/p>\n<p>                            Connect with a Mesothelioma Doctor<\/p>\n<p>\n                    Find a Top Specialist Near You                <\/p>\n","protected":false},"excerpt":{"rendered":"A clinical trial testing a new type of cell therapy for mesothelioma is actively recruiting patients at sites&hellip;\n","protected":false},"author":2,"featured_media":582736,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-582735","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/582735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=582735"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/582735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/582736"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=582735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=582735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=582735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}